{"entity":{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","aka":["Newcastle upon Tyne Hospitals NHS Foundation Trust","Freeman Hospital","Newcastle University Centre for Cancer"],"tldr":"Newcastle's cancer centre serves the North East and Cumbria; its chemists and pharmacologists discovered rucaparib, the first PARP inhibitor to reach patients, and Ruth Plummer led its first-in-human trial in 2003, while the Wolfson centre leads medulloblastoma research.","summary":"The Northern Centre for Cancer Care at the Freeman Hospital and the Great North Children's Hospital provide tertiary cancer care for the North East and Cumbria, while Newcastle University's Centre for Cancer is a Cancer Research UK centre with a drug discovery unit. Newcastle chemists and pharmacologists (Hilary Calvert, Nicola Curtin, Herbie Newell, Bernard Golding) discovered rucaparib with Agouron, and Ruth Plummer led the first-in-human trial of a PARP inhibitor in 2003. The Wolfson Childhood Cancer Research Centre is a leader in medulloblastoma and childhood leukaemia biology, and the Sir Bobby Robson Cancer Trials Research Centre runs early-phase trials. Newcastle also hosts national programmes in ageing and cancer and in mitochondrial disease.","asOf":"2026-09-09","links":[{"label":"Cancer services","url":"https://www.newcastle-hospitals.nhs.uk/services/cancer-services/"},{"label":"Newcastle University Centre for Cancer","url":"https://www.ncl.ac.uk/cancer/"}],"tags":[],"related":[],"cancers":["ovarian","neuroblastoma","all-leukemia","glioblastoma","pancreatic","colorectal","nsclc","lung-cancer","skin-cancer","basal-cell-carcinoma"],"sections":["targeted-therapy","drug-discovery"],"technologies":["parp-inhibitor","synthetic-lethality-approaches","ai-drug-design"],"targets":["parp","brca"],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":["synthetic-lethality"],"trials":["capp2"],"people":["ruth-plummer","steven-clifford","graham-jackson","john-burn","alastair-greystoke"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Newcastle upon Tyne","country":"GB","lat":54.999,"lng":-1.616,"institutionType":"hospital","website":"https://www.newcastle-hospitals.nhs.uk/services/cancer-services/","university":"Newcastle University","programs":["PARP inhibitor discovery (rucaparib)","Sir Bobby Robson early-phase trials unit","Childhood cancer research","CRUK Newcastle Drug Discovery Unit"]},"route":"/institutions/newcastle-cancer-centre/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"institution":[{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/"},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"northern-cancer-alliance","kind":"institution","name":"Northern Cancer Alliance","route":"/institutions/northern-cancer-alliance/"}],"term":[{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/"}],"trial":[{"id":"capp2","kind":"trial","name":"CAPP2","route":"/trials/capp2/"},{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/"},{"id":"precision-panc","kind":"trial","name":"Precision-Panc","route":"/trials/precision-panc/"}],"person":[{"id":"alastair-greystoke","kind":"person","name":"Alastair Greystoke","route":"/people/alastair-greystoke/"},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/"},{"id":"john-burn","kind":"person","name":"John Burn","route":"/people/john-burn/"},{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/"},{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/"}],"collection":[{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/"}]}}